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Summary. In this review we attempt to determine the role of
calcium channel blockers in preventing cardiovascular
sequelae in patients with both hypertension and diabetes
mellitus. The data have been collected from three sources:
post-hoc analyses of subgroups of diabetic patients in pla-
cebo-controlled hypertension trials (SHEP, Syst-Eur, Syst-
China); stepped-care blood pressure-oriented trials (HOT);
and comparative trials focusing primarily on metabolic as-
pects and intermediate endpoints (ABCD, FACET).
On balance, the data seem to indicate that long-acting
calcium channel blockers score remarkably well in prevent-
ing cardiovascular complications in diabetic hypertensive
patients.
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Hypertension and diabetes are widely recognized as
mutually reinforcing factors leading to premature car-
diovascular complications and renal disease [1]. The
present review is intended to highlight the potential of
blood pressure control in the prevention of cardiovas-
cular sequelae in diabetic patients with hypertension.
Whenever possible, the ef~cacy of long-acting calcium
channel blockers has been compared either with pla-
cebo or with other antihypertensive drugs. The vast
majority of patients under consideration had type 2
diabetes and were under appropriate conventional an-
tidiabetic control.
Overview of Trials
The main hypertension trials that have included dia-
betic patients are listed in Table 1. A major contribu-
tion in this area has originated from the Systolic Hy-
pertension in the Elderly Program (SHEP). In this
trial [2,3], most cardiovascular events were reduced to
a similar degree by chlorthalidone-based treatment
(vs. placebo) in diabetic and nondiabetic hypertensive
patients. It is noteworthy that coronary events were
reduced even more in diabetic than in nondiabetic pa-
tients. This  overall  outcome  turned  out to be more
favorable than might have been expected on the basis
of the rather negative metabolic pro~le, including insu-
lin resistance, of thiazide-type diuretics [4].
More recently, a similar post-hoc subgroup analysis
has been performed in the study population of the Sys-
tolic Hypertension in Europe (Syst-Eur) trial [5,6] (Ta-
ble 2). In that trial, 492 (10.5%) of 4695 randomized
patients with isolated systolic hypertension had diabe-
tes [5]. These diabetic patients had on average a 1.7
mmHg higher systolic blood pressure and a 1.1 mmHg
lower diastolic blood pressure than the nondiabetic pa-
tients. Treatment steps in the double-blind Syst-Eur
trial were nitrendipine (10–40 mg/d), enalapril (5–20
mg/d) and hydrochlorothiazide (12.5–25 mg/d) titrated
or combined to reduce systolic pressure by 20 mmHg
to below 150 mmHg; in the control group, matching
placebo tablets were used similarly. After a median
follow-up of 2 years, blood pressure, corrected for
placebo effects, was reduced to a similar extent in dia-
betics and nondiabetics (systolic/diastolic pressure:
28.6/23.9 mmHg and 210.3/24.6 mmHg, respec-
tively). Nevertheless, the bene~ts in preventing end-
points were considerably greater in diabetic than in
nondiabetic patients, as indicated in Table 2. Further-
more, the bene~t conferred by active treatment was
similar in the patients who remained on monotherapy
Address for correspondence: Jan A. Staessen, M.D., Ph.D., Stu-
diecoördinatiecentrum, Laboratorium Hypertensie, Campus
Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium. E-mail:
jan.staessen@med.kuleuven.ac.be
Received 27 May 1999; receipt/review time 14 days; accepted 14
June 1999
49
Cardiovascular Drugs and Therapy 2000;14:49–53
© 2000 Kluwer Academic Publishers. Manufactured in The Netherlands.
with nitrendipine to that in those who progressed to
combined therapy [7].
The SHEP [2,3] and Syst-Eur [5,6] trials were re-
markably similar in design and size, with only one prin-
cipal difference, i.e., the choice of the ~rst-line antihy-
pertensive drug: chlorthalidone and nitrendipine,
respectively. This fact invited us to compare the results
obtained in these two trials. As shown in Table 3, the
validity of such a comparison is sustained by the simi-
lar net decreases in blood pressure, the similar risks in
the placebo groups regardless of the absence or pres-
ence of diabetes, and the identity of relative outcome
bene~ts of active treatment in the nondiabetics. The
only major difference occurred in the actively treated
diabetic subgroups, where three major events declined
2–4 times as much on treatment with a calcium channel
blocker as on treatment with a thiazide (SHEP). Our
conclusion is therefore at variance with the recommen-
dation by the SHEP investigators to prescribe low-
dose diuretics as the ~rst step of antihypertensive
treatment in diabetic patients with hypertension [3].
To the contrary, we would instead advise the use of
nitrendipine-like calcium channel blockers as the ~rst
choice, in view of the event-free survival and vascular
protection observed in the Syst-Eur trial [5].
In the placebo-controlled Systolic Hypertension in
China (Syst-China) trial [8], the ~rst-line active medi-
cation was also nitrendipine (10–40 mg/d), to which
captopril (12.5–50 mg/d) and/or hydrochlorothiazide
(12.5–50 mg/d) could be added to achieve blood pres-
sure control. In the placebo group, diabetes raised the
risk of all endpoints 2–3 times (p # 0.05). However,
active treatment reduced the excess risk associated
with diabetes to a nonsigni~cant level except for car-
diovascular mortality. Thus, in line with the Syst-Eur
~ndings [5,6], the Chinese trial showed that treatment
starting with a dihydropyridine calcium channel
blocker was particularly bene~cial in older diabetic pa-
tients with systolic hypertension [8].
The mechanisms underlying the particular bene~t
of calcium channel blockers are a matter of speculation;
they may well be multiple. A major role may be attrib-
utable to the absence of metabolic side effects from
calcium channel blockers, such as glucose intolerance
and perturbations of the serum lipids pro~le [9,10], to
which thiazide-treated diabetic patients seem  to be
particularly vulnerable [11]. In addition, calcium chan-
nel blockers may provide renal protection [12,13] and
may exert bene~cial effects on the  rheology of  the
blood [14] and on endothelial function [15,16]. The rele-
vance of these hypothetic mechanisms remains open to
further investigation.
The Hypertension Optimal Treatment (HOT) Study
[17,18] produced con~rmatory evidence on a positive
interaction between calcium channel blockade and the
presence of diabetes in older hypertensive patients. In
this trial (Table 1), no less than 18,790 hypertensive
Table 1. Trials reporting outcomes in diabetic patients with
hypertension
Diabetics
Trial (references) No. (%)* Main study drugs
Placebo-controlled
SHEP [2,3] 590 (12.3) Chlorthalidone† vs. placebo
Syst-Eur [5,6] 492 (10.5) Nitrendipine† vs. placebo
Syst-China [8] 98 (4.1) Nitrendipine† vs. placebo
Other designs
ABCD [19] 470 (100)‡ Nisoldipine vs. enalapril†
FACET [20] 380 (100) Amlodipine vs. fosinopril†
HOT [17,18] 1501 (8.0) Felodipine to reach
diastolic pressure
# 90 mmHg† vs.
# 80 mmHg
*Number of diabetics (percentage of total number of patients en-
rolled).
†Identi~es the treatment on which outcome was signi~cantly better
in diabetic patients with hypertension.
‡Results in 480 normotensive diabetic patients not reported.
Table 2. Bene~t of antihypertensive treatment in diabetic and nondiabetic patients randomized in the Syst-Eur trial
Diabetics Nondiabetics
Active Active
Placebo* treatment* Placebo* treatment*
Nature of endpoint (N 5 240) (N 5 252) Change (%)† p‡ (N 5 2057) (N 5 2146) Change (%)† p‡
Mortality
Total 45.1 (26) 26.4 (16) 241 (269, 9) 0.09 21.6 (111) 19.8 (107) 28 (230, 20) 0.55
Cardiovascular 27.8 (16) 8.3 (5) 270 (289, 219) 0.01 11.9 (61) 10.0 (54) 216 (242, 22) 0.37
Fatal and nonfatal endpoints
All cardiovascular 57.6 (31) 22.0 (13) 262 (280, 219) 0.002 31.4 (155) 23.5 (124) 225 (241, 25) 0.02
Stroke 26.6 (15) 8.3 (5) 269 (289, 214) 0.02 12.3 (62) 7.8 (42) 236 (257, 25) 0.02
Cardiac endpoints 27.1 (15) 1.17 (7) 257 (282, 6) 0.06 19.7 (99) 15.4 (82) 222 (242, 5) 0.10
*Endpoints per 1000 patient-years (number of events).
†Change with active treatment, with 95% con~dence interval between parentheses.
‡Signi~cance for the comparison between placebo and active treatment.
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patients from 26 countries (mean age 61.5 years) were
randomized to reach one of three target levels of dia-
stolic blood pressure (90, 85, or 80 mmHg). The calcium
channel blocker felodipine served as the mainstay of
treatment (5–10 mg/d), with the potential addition of
angiotensin-converting enzyme   inhibitors or beta-
blockers. The actual blood pressure levels attained in
the three groups turned out to be closer than expected:
143.7/85.2 mmHg, 141.4/83.2 mmHg, and 139.7/81.1
mmHg, respectively. Table 4 shows the effects of ran-
domization to a target diastolic blood pressure of 90
and 80 mmHg, respectively. With the exception of a
greater incidence of myocardial infarctions in the sub-
population randomized to 90 mmHg compared with the
one targeted to 80 mmHg, there were in the study
population as a whole no differences in outcome. By
contrast, the diabetic patients (8%) randomized to a
goal diastolic blood pressure of 80 mmHg fared
signi~cantly better than those assigned to attaining a
diastolic blood pressure of 90 mmHg. In fact, the risk
of fatal and nonfatal cardiovascular events was 2 to 3
times higher in the latter group. This substantial im-
pact of a rather modest reduction in the achieved dia-
stolic blood pressure (24.1 mmHg) may come as a sur-
prise. However, in the Syst-Eur diabetic subgroup [5],
similar differences  in endpoint rates  have been  ob-
served (Table 2) in the face of equally modest net re-
ductions in diastolic blood pressure [6].
These mutually corroborating results obtained in-
dependently in two large, randomized, prospective tri-
als of different design are ostensibly at variance with
the results of some earlier studies [19,20]. The Ap-
propriate Blood Pressure Control in Diabetes (ABCD)
trial was originally designed to compare progression
of diabetic nephropathy under treatment with the
angiotensin-converting enzyme inhibitor enalapril or
with the calcium channel blocker nisoldipine. Hyper-
tensive patients (N 5 470) were randomized to either
Table 3. Results of the Systolic Hypertension in the Elderly Program (SHEP) and the Systolic Hypertension in Europe trial
(Syst-Eur) in diabetic and nondiabetic patients
Diabetics Nondiabetics
SHEP* Syst-Eur* SHEP* Syst-Eur*
N (%) 590 (12.3) 492 (10.5) 4149 (87.7) 4203 (89.5)
Mean blood pressure reduction†
Systolic (mmHg) 29.8 28.6 212.5 210.3
Diastolic (mmHg) 22.2 23.9 24.1 24.6
Risk in placebo group‡
Total mortality 35.6 45.1 21.8 21.6
Cardiovascular endpoints 63.0 55.0 36.8 28.9
Stroke 28.8 26.6 15.0 12.3
Coronary events 32.2 23.1 15.2 12.4
Change with active treatment (%)§
Mortality 226 (254, 18) 264 (283, 225) 215 (232, 6) 218 (240, 13)
All cardiovascular endpoints 234 (254, 26) 268 (284, 235) 234 (245, 221) 230 (247, 28)
Stroke 222 (255, 34) 286 (296, 258) 238 (254, 217) 239 (260, 27)
Coronary events 256 (275, 223) 258 (287, 37) 219 (238, 5) 222 (247, 17)
*In the SHEP trial [2,3], active treatment consisted of chlorthalidine (12.5–25 mg/d) with the possible addition of atenolol (25–50 mg/d) or reserpine
(0.05–0.1 mg/d); in the Syst-Eur trial [5,6], active treatment consisted of nitrendipine (10–40 mg/d) with the possible addition of enalapril (5–20
mg/d) and/or hydrochlorothiazide (12.5–25 mg/d).
†The mean effect of active treatment on blood pressure was corrected for baseline and placebo.
‡Rate expressed as events per 1000 patient-years.
§The changes with active treatment were calculated by Cox regression with adjustments applied for sex, age, smoking, systolic and diastolic blood
pressure at baseline, electrocardiographic abnormalities (SHEP) or previous cardiovascular complications (Syst-Eur) at baseline, and race (SHEP)
or residence in western Europe (Syst-Eur).
Table 4. Relative risks in the Hypertension Optimal
Treatment trial* [19,20] in patients randomized to a target
diastolic blood pressure of 90 vs. 80 mmHg
All patients Diabetics only
Number of patients randomized
to 90 mmHg 6264 501
to 80 mmHg 6262 499
Relative risk†
Total mortality 0.91 (0.74–1.10) 1.77 (0.98–3.21)o
Cardiovascular
mortality 0.90 (0.68–1.21) 3.00 (1.28–7.08)a
Major cardiovascular
events 1.07 (0.89–1.28) 2.06 (1.24–3.44)b
Myocardial infarction 1.37 (0.99–1.91)a 2.01 (0.81–4.97)
Stroke 1.05 (0.79–1.41) 1.43 (0.68–2.99)
*Felodipine (5–10  mg/d),  unless contraindicated,  was  the  ~rst-line
antihypertensive treatment in all patients.
†95% con~dence interval presented between parentheses:
o, p 5 0.07; a, p # 0.05; b, p # 0.01.
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active enalapril (5–40 mg/d) plus nisoldipine placebo
or to active nisoldipine (10–60 mg/d) plus enalapril pla-
cebo tablets, all administered in a double-blind man-
ner. After 87 months of study, the Data and Safety
Monitoring Committee observed a statistically sig-
ni~cant difference in the rates of cardiovascular
events between the two groups (i.e., a preponderance
of myocardial infarctions in the nisoldipine group) and
hence recommended stopping the double-blind regi-
men. This decision to prematurely stop the trial is
open to criticism. Myocardial infarction was not a pre-
speci~ed endpoint. Treatment status at the time of the
myocardial infarctions was not reported. This is im-
portant because premature discontinuation of the dou-
ble-blind study medication and the addition of beta-
blockers and thiazides to the study drugs may well
have been in favor of the enalapril group. No ~rst-
ever event analysis has been made available. All these
de~ciencies may have enhanced the chance of a biased
~nding.
The Fosinopril versus Amlodipine Cardiovascular
Events Trial (FACET) was an open-label randomized
study in patients with hypertension and type 2 diabe-
tes [20]. Its primary purpose was to assess treatment-
related differences in  diabetes  control, serum  lipids
and renal function. The patients were randomly as-
signed to receive fosinopril (20 mg/d) or amlodipine (10
mg/d) as the ~rst-line antihypertensive drug. If blood
pressure remained uncontrolled, the alternative drug
was added to the initial regimen. According to inten-
tion-to-treat analysis, patients receiving fosinopril as
the ~rst-line drug appeared to have signi~cantly or
lower risk of the combined outcomes of acute myocar-
dial infarction, stroke, or hospitalization for angina
than those receiving amlodipine (14/189 vs. 27/191
events). The interpretation of the above results is
handicapped by a number of confounding factors. First
of all, 58 patients randomized to fosinopril (30.7%) and
50 from the amlodipine group (26.2%) ended up receiv-
ing the combination of both drugs, which makes any
sensible interpretation rather precarious. An even
more serious objection arises from the fact that mi-
croalbuminuria at entry was signi~cantly higher in the
amlodipine group (24 6 1 lg/min) than in the fosinopril
group (20 6 1 lg/min; p , 0.05). A difference of this
order of magnitude may well have been crucial deter-
minant of the uneven outcome, since in type 2 diabetic
patients the extent of microalbuminuria is at least as
accurate in predicting cardiovascular  morbidity and
mortality as that of cholesterol levels, hypertension,
smoking, and even preexisting coronary artery disease
[21–23].
Although the FACET authors recognize the fact
that their trial was unsuited to detecting a difference
in vascular events between the two treatment groups
[20], they nevertheless maintain their preference for
angiotensin-converting enzyme inhibitors versus cal-
cium channel blockers as ~rst-line treatment of dia-
betic hypertensive patients.
Conclusion
One dif~culty in assessing the merits or hazards of cal-
cium channel blockers vs. other drug classes in diabetic
hypertensive patients is that the latter have often been
recruited as subgroups in larger trials in hypertension.
This situation has necessarily turned the evaluation of
the treatment effects in the diabetic subgroups into a
post-hoc exercise. In our view, this handicap is a limited
one that has been largely compensated for by the strict
adherence in the statistical analyses to predetermined,
unadulterated endpoints. In this regard, the parent tri-
als such as SHEP [2,3], Syst-Eur [5,6], Syst-China [8],
and HOT [17,18] appear to have distinguished them-
selves as compared to the “adaptive” trials that devi-
ated from their original design [19,20] in midstream.
The evidence in favor of using dihydropiridine-type
long-acting calcium channel blockers, exempli~ed
above by nitrendipine and felodipine, as ~rst-line anti-
hypertensive treatment in diabetic hypertensive pa-
tients seems to be overwhelming both in quantitative
and qualitative terms when considering cardiovascular
outcome.
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